Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.

Literature DB >> 19961483

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.

Irina Idler, Krzysztof Giannopoulos, Thorsten Zenz, Nupur Bhattacharya, Maria Nothing, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19961483 DOI： 10.1111/j.1365-2141.2009.08014.x

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

21 in total

1. Lenalidomide enhances anti-myeloma cellular immunity.

Authors: Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal: Cancer Immunol Immunother Date: 2012-06-24 Impact factor: 6.968

2. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

Authors: Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael Carducci; Samuel Denmeade; Charles Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario Eisenberger
Journal: Clin Cancer Res Date: 2010-10-26 Impact factor: 12.531

3. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.

Authors: Preetesh Jain; Mohammad Javdan; Franziska K Feger; Pui Yan Chiu; Cristina Sison; Rajendra N Damle; Tawfiqul A Bhuiya; Filiz Sen; Lynne V Abruzzo; Jan A Burger; Andreas Rosenwald; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941

Review 4. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors: Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal: Blood Adv Date: 2017-09-26

5. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Authors: Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson
Journal: Clin Cancer Res Date: 2017-03-01 Impact factor: 12.531

Review 6. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors: D Atanackovic; T Luetkens; N Kröger
Journal: Leukemia Date: 2013-10-23 Impact factor: 11.528

7. Lenalidomide potentiates CD4⁺CD25⁺Treg-related suppression of lymphoma B-cell proliferation.

Authors: Monika Anna Grygorowicz; Ilona Sara Borycka; Eliza Nowak; Ewa Paszkiewicz-Kozik; Grzegorz Rymkiewicz; Katarzyna Błachnio; Marzena Biernacka; Mateusz Bujko; Jan Walewski; Sergiusz Markowicz
Journal: Clin Exp Med Date: 2016-03-10 Impact factor: 3.984

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.

1. Lenalidomide enhances anti-myeloma cellular immunity.

2. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

3. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.

Review 4. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

5. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Review 6. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

7. Lenalidomide potentiates CD4⁺CD25⁺Treg-related suppression of lymphoma B-cell proliferation.

Review 8. Immune reconstitution in chronic lymphocytic leukemia.

Review 9. T-regulatory cells: key players in tumor immune escape and angiogenesis.

Review 10. Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.

1. Lenalidomide enhances anti-myeloma cellular immunity.

2. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

3. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.

Review 4. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

5. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Review 6. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

7. Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.

Review 8. Immune reconstitution in chronic lymphocytic leukemia.

Review 9. T-regulatory cells: key players in tumor immune escape and angiogenesis.

Review 10. Lenalidomide alone and in combination for chronic lymphocytic leukemia.

7. Lenalidomide potentiates CD4⁺CD25⁺Treg-related suppression of lymphoma B-cell proliferation.